ASCO 2022 Conference Coverage

 

ASCO 2022 Conference Coverage
T

Lecture Summary - ASCO 2022 on Perioperative Ramucirumab + FLOT vs. FLOT Alone for Resectable Esophagogastric Adenocarcinoma With High Rate of Signet Cell Component: Final Results of the Multicenter, Randomized Phase II/III Trial

By ASCO 2022 Conference Coverage FEATURING Thorsten Oliver Götze
By ASCO 2022 Conference Coverage FEATURING Thorsten Oliver Götze
9 views
June 14, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
GI
10:11
ASCO 2022 Conference Coverage

ASCO 2022 on Atezolizumab + Bevacizumab vs Lenvatinib or Sorafenib i…

Feat. M. Rimini
07:56
ASCO 2022 Conference Coverage

ASCO 2022 on RAS Co-Mutation and Early Onset Disease Represent an Ag…

Feat. B. Johnson
03:33
ASCO 2022 Conference Coverage

ASCO 2022 Patient-Reported Outcomes From the Phase 3 HIMALAYA Study …

Feat. P. Galle
02:15
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Adjuvant Chemotherapy Guided by ctDNA An…

Feat. J. Tie
07:51
ASCO 2022 Conference Coverage

Updates on the PARADIGM Trial: PAN + mFOLFOX6 vs. BEV + mFOLFOX6 as …

Feat. T. Yoshino
01:21
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Phase 3 CAIRO5 Study: FOLFOXIRI + Bev…

Feat. C. Punt
07:57
ASCO 2022 Conference Coverage

ASCO 2022 on Phase I/II Trial of Encorafenib, Cetuximab, & Nivol…

Feat. V. Morris
59
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Phase I/II Trial of Encorafenib, Cetu…

Feat. V. Morris
07:35
ASCO 2022 Conference Coverage

ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study o…

Feat. A. Ruth He, F. Banovac
40
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on an Open-Label, Multicenter, Randomize…

Feat. A. Ruth He, F. Banovac
58
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on EA2183: A Phase III Study of Consolid…

Feat. N. Uboha
06:44
ASCO 2022 Conference Coverage

ASCO 2022 on EA2183: A Phase III Study of Consolidative RT in Patien…

Feat. N. Uboha
05:40
ASCO 2022 Conference Coverage

ASCO 2022 Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant…

Feat. D. Takahari
11:07
ASCO 2022 Conference Coverage

ASCO 2022 The Differential Response to Immune Checkpoint Inhibitors …

Feat. M. Khushman
06:33
ASCO 2022 Conference Coverage

ASCO 2022 Testing of a Machine Learning Model for Ability to Predict…

Feat. M. Sun
05:53
ASCO 2022 Conference Coverage

ASCO 2022 on a Regional Subgroup Analysis of the Phase 3 TOPAZ-1 Stu…

Feat. A. Vogel
04:54
ASCO 2022 Conference Coverage

ASCO 2022 IMMUTACE - A Biomarker-Orientated Phase II, Single-Arm, Op…

Feat. A. Vogel
05:30
ASCO 2022 Conference Coverage

ASCO 2022 on SWOG S2012: Randomized Phase II/III Trial of 1L Platinu…

Feat. D. Zhen
05:12
ASCO 2022 Conference Coverage

ASCO 2022 IMMUNIB Trial: A Single-Arm, Phase II Study Evaluating Saf…

Feat. A. Vogel
10:29
ASCO 2022 Conference Coverage

ASCO 2022 Using cfDNA to Identify Guideline-Relevant Biomarkers for …

Feat. P. Kasi
58
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Targeting HER2 Mutation-Positive Advance…

Feat. J. Harding
54
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on ctDNA Profile in Pancreatic Ductal Ad…

Feat. F. Esposito
09:42
ASCO 2022 Conference Coverage

ASCO 2022 Targeting HER2 Mutation-Positive Advanced Biliary Tract Ca…

Feat. J. Harding
05:39
ASCO 2022 Conference Coverage

ASCO 2022 on ctDNA Profile in Pancreatic Ductal Adenocarcinoma and P…

Feat. F. Esposito
04:22
ASCO 2022 Conference Coverage

ASCO 2022 on the Multicenter Phase Ib US Trial of Salvage CT041 CLDN…

Feat. G. Botta
01:26
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Multicenter Phase Ib US Trial of …

Feat. G. Botta
01:13
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Investigating a Switch Maintenance Co…

Feat. S. Stintzing
55
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Perioperative Ramucirumab + FLOT vs. …

Feat. T. Oliver Götze
07:37
ASCO 2022 Conference Coverage

ASCO 2022 on Investigating a Switch Maintenance Concept With 5-FU + …

Feat. S. Stintzing
08:49
ASCO 2022 Conference Coverage

ASCO 2022 on the Phase 2/3 Study of an Individualized Neoantigen Vac…

Feat. J. Hecht
34
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Phase 2/3 Study of an Individuali…

Feat. J. Hecht
06:16
ASCO 2022 Conference Coverage

ASCO 2022 on NSABP FC-10: A Phase Ib Study of Pembro + Pemetrexed &a…

Feat. J. Krauss
34
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on mFOLFOXIRI + PAN vs. mFOLFOX6/PAN as …

Feat. C. Cremolini
11:34
ASCO 2022 Conference Coverage

ASCO 2022 on mFOLFOXIRI + PAN vs. mFOLFOX6/PAN as Initial Treatment …

Feat. C. Cremolini
09:20
ASCO 2022 Conference Coverage

ASCO 2022 on the Comparative Efficacy of Novel Combination IO Strate…

Feat. C. Fulgenzi
40
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Multicenter Phase II Study of Abemaci…

Feat. R. Kelly
05:15
ASCO 2022 Conference Coverage

ASCO 2022 on Multicenter Phase II Study of Abemaciclib & Ramucir…

Feat. R. Kelly
31
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 NEOPRISM CRC: Neoadjuvant Pembrolizumab …

Feat. K. Shiu
15:40
ASCO 2022 Conference Coverage

ASCO 2022 NEOPRISM CRC: Neoadjuvant Pembrolizumab Stratified to Tumo…

Feat. K. Shiu
01:02
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Pembrolizumab + mFOLFOX7/FOLFIRI for …

Feat. R. Kim
08:41
ASCO 2022 Conference Coverage

ASCO 2022 on KEYNOTE-651: Pembrolizumab + mFOLFOX7/FOLFIRI for mCRC:…

Feat. R. Kim
43
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (C…

Feat. M. Overman
04:11
ASCO 2022 Conference Coverage

ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (COMMIT) Phase 3 Stu…

Feat. M. Overman
39
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Immunotherapy With Nivolumab After Progr…

Feat. A. Rauthan
09:02
ASCO 2022 Conference Coverage

ASCO 2022 Immunotherapy With Nivolumab After Progression on Lenvatin…

Feat. A. Rauthan
23
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updates on Infigratinib vs. Gemcitabine …

Feat. G. Abou-Alfa
06:42
ASCO 2022 Conference Coverage

ASCO 2022 on PROOF 301 Trial: Updates on Infigratinib vs. Gemcitabin…

Feat. G. Abou-Alfa